The RAV12 monoclonal antibody recognizes the N-linked glycotope RAAG12: Expression in human normal and tumor tissues

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 9, 2009, Pages 1403-1412

  Coberly, Suzanne K ^a,b   Chen, Francine Z ^a   Armanini, Mark P ^a   Chen, Yan ^a   Young, Peter F ^a   Mather, Jennie P ^a   Loo, Deryk T ^a  

^a MacroGenics Inc   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RAV12; RAAG12 ANTIGEN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; APICAL MEMBRANE; ARTICLE; BREAST CANCER; CELLULAR DISTRIBUTION; COLON ADENOCARCINOMA; ESOPHAGUS CANCER; GASTROINTESTINAL MUCOSA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CANCER; METASTASIS; NORMAL HUMAN; OVARY CANCER; PANCREAS ADENOCARCINOMA; PROSTATE CARCINOMA; STAINING;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MICE; MICE, SCID; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69749108893     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Dube DH, Bertozzi CR. Glycans in cancer and inflammation - potential for therapeutics and diagnostics. Nat Rev Drug Discov. 2005;4:477-488. (Pubitemid 40861990)
2. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A. 2002;99:10231-10233. (Pubitemid 34906955)
3. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer. 2005;5:526-542.
4. Kim YS, Yuan M, Itzkowitz SH, et al. Expression of LeY and extended LeY blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissues. Cancer Res. 1986;46:5985-5992. (Pubitemid 17178016)
5. Zhang S, Zhang HS, Cordon-Cardo C, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. blood group-related antigens. Int J Cancer. 1997;73:50-56. (Pubitemid 27445990)
6. Dettke M, Palfi G, Loibner H. Activation-dependent expression of the blood group-related lewis Y antigen on peripheral blood granulocytes. J Leukoc Biol. 2000;68:511-514. (Pubitemid 30764583)
7. Hellstrom I, Garrigues HJ, Garrigues U, Hellstrom KE. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res. 1990;50:2183-2190. (Pubitemid 20115097)
8. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996;56:5309-5318. (Pubitemid 27011703)
9. Muramatsu T. Carbohydrate signals in metastasis and prognosis of human carcinomas. Glycobiology. 1993;3:291-296. (Pubitemid 23281276)
10. Klinger M, Farhan H, Just H, et al. Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. Cancer Res. 2004; 64:1087-1093. (Pubitemid 38176914)
11. Loo D, Pryer N, Young P, et al. The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo. Mol Cancer Ther. 2007;6:856-865. (Pubitemid 46554555)
12. Li JC, Li R. RAV12 accelerates the desensitization of Akt/PKB pathway of insulin-like growth factor I receptor signaling in COLO205. Cancer Res. 2007; 67:8856-8864. (Pubitemid 47437462)
13. Mather JP, Young PF, inventors; Raven Biotechnologies, Inc, assignee. Animal model for toxicology and dose prediction. US patent 10,448,766. 2004.
14. Parmar H, Young P, Emerman JT, et al. A novel method for growing human breast epithelium in vivo using mouse and human mammary fibroblasts. Endocrinology. 2002;143:4886-4896. (Pubitemid 35397628)
15. Acres B, Limacher JM. MUC1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines. 2005;4:493-502. (Pubitemid 41297296)
16. Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases. Mod Pathol. 2004;17:180-188. (Pubitemid 41656514)
17. Walsh MD, Hohn BG, Thong W, et al. Mucin expression by transitional cell carcinomas of the bladder. Br J Urol. 1994;73:256-262. (Pubitemid 24134729)
18. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer. 2001;91:1973-1982. (Pubitemid 32476360)
19. Gilewski T, Adluri S, Ragupathi G, et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res. 2000;6:1693-1701. (Pubitemid 30305061)
20. Karanikas V, Thynne G, Mitchell P, et al. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J Immunother. 2001;24:172-183. (Pubitemid 32183063)
21. Ramanathan RK, Lee KM, McKolanis J, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother. 2005;54:254-264. (Pubitemid 40174243)
22. Scholl SM, Balloul JM, Le Goc G, et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother. 2000;23:570-580. (Pubitemid 30679333)
23. Yamamoto K, Ueno T, Kawaoka T, et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res. 2005; 25:3575-3579. (Pubitemid 41105243)
24. Apostolopoulos V, Pietersz GA, Tsibanis A, et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 2006;8:R27. (Pubitemid 43899331)
25. Kontani K, Taguchi O, Ozaki Y, et al. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med. 2003;12:493-502.
26. de Bono JS, Rha SY, Stephenson J, et al. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol. 2004;15:1825-1833. (Pubitemid 40012249)
27. Gibson MC, Perrimon N. Apicobasal polarization: epithelial form and function. Curr Opin Cell Biol. 2003;15:747-752. (Pubitemid 37487968)
28. Pervez S, Kirkland SC, Epenetos AA, et al. Effect of polarity and differentiation on antibody localization in multicellular tumour spheroid and xenograft models and its potential importance for in vivo immunotargeting. Int J Cancer. 1989;44:940-947. (Pubitemid 20007997)